NCT06116565CompletedPhase 2
A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis
An Multi-center, Open-label, Single-arm Phase 2 Study to Evaluate the Long-term Safety and Efficacy of CM310 in Subjects With Moderate-to-severe Atopic Dermatitis
Source: ClinicalTrials.gov · Last updated 20 Aug 2026
Brief summary (registry, in English)
This is a multi-center, open-label phase 2 study to evaluate the long-term safety and efficacy of CM310 in subjects with moderate-to-severe atopic dermatitis.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 263 (actual)
- First submitted
- 30 Oct 2023
- Start date
- 21 Dec 2023
- Primary completion date
- 26 Nov 2025
- Lead sponsor
- Keymed Biosciences Co.Ltd
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT06116565
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 263
- From 21 Dec 2023 to the primary completion date, 26 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Not enough washing-out period for previous therapy.
- Concurrent disease/status which may potentially affect the efficacy/safety judgement.
Other
- Major surgeries are planned during the study period.
Who the study is looking for
- Have the ability to understand the study and voluntarily sign a written informed consent form (ICF).
- Age ≥ 18 and ≤ 75 years old.
- With Atopic Dermatitis.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.